Drugs Containing Excipient (Inactive Ingredient) CI 77499

« Back to Dashboard

Generic drugs containing CI 77499 excipient

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	indomethacin	50090-0054	CI 77499
A-S Medication Solutions	indomethacin	50090-0055	CI 77499
A-S Medication Solutions	diclofenac sodium	50090-0538	CI 77499
A-S Medication Solutions	diclofenac sodium	50090-0539	CI 77499
A-S Medication Solutions	diclofenac sodium	50090-0540	CI 77499

CI 77499 Market Dynamics and Financial Trajectory in Pharmaceutical Excipients

Last updated: October 5, 2026

CI 77499 is the cosmetic color index designation for black iron oxide, generally associated with magnetite, Fe3O4. In pharmaceutical products, it is used primarily as a pigment in film coatings, hard capsules, tablets, and identification systems rather than as a functional excipient. The market is fragmented, specification-driven, and difficult to size because suppliers report iron oxide revenue across pigments, coatings, plastics, cosmetics, food, and pharmaceuticals.

The financial outlook is stable rather than high-growth. Demand follows solid-dose pharmaceutical production, generic-drug volumes, capsule and tablet launches, and continued use of color coding. Margin expansion depends on pharmaceutical-grade qualification, low extractables, tight particle-size control, regulatory documentation, and supply reliability. Public companies generally do not disclose CI 77499 revenue separately.

What is CI 77499 and how is it used in pharmaceuticals?

CI 77499 is black iron oxide. Its principal chemical composition is magnetite, Fe3O4, although commercial materials can contain variable proportions of iron oxides and require grade-specific characterization.

Attribute	Data
Cosmetic Color Index	CI 77499
Common name	Black iron oxide
Chemical identity	Primarily Fe3O4
CAS reference commonly used	1317-61-9
Pharmaceutical role	Colorant, coating pigment, capsule and tablet identification agent
Physical form	Fine black powder or dispersed pigment
Principal dosage forms	Film-coated tablets, hard capsules, multiparticulates
Primary commercial function	Appearance, product identification, brand differentiation, light and color control
Regulatory classification	Color additive or excipient status depends on jurisdiction and route of administration

CI 77499 is not generally used to improve dissolution, compressibility, stability, or bioavailability. Its value lies in visual identification and manufacturing consistency. In tablets, it is commonly incorporated into aqueous or solvent-based coating systems. In capsules, the pigment can be used in the shell or printing system.

The excipient designation is jurisdiction-dependent. In the United States, iron oxide use is governed by the applicable color-additive and drug regulations, including 21 C.F.R. provisions for iron oxides and FDA inactive-ingredient records. In the European Union, iron oxides are associated with E172 for food and pharmaceutical applications, while CI 77499 is the corresponding cosmetic nomenclature. Product-specific authorization and route restrictions remain important. [1][2][3]

How large is the CI 77499 pharmaceutical market?

No authoritative public source reports a standalone global market size for pharmaceutical CI 77499. Market reports generally aggregate black iron oxide with other synthetic iron oxides or combine pharmaceutical pigments with food, cosmetic, construction, plastics, and industrial coatings.

The pharmaceutical segment is small compared with construction and industrial pigment demand. Its economic importance is higher than its volume share because pharmaceutical customers require:

• Controlled heavy-metal and elemental-impurity profiles
• Lot-to-lot color consistency
• Documented particle-size distribution
• Microbiological control
• GMP-oriented manufacturing and change control
• Regulatory support by market
• Low extractables and leachables
• Stable supply over a product’s commercial life

The market can therefore be divided into three layers:

Market layer	Demand profile	Pricing characteristics
Commodity black iron oxide	High-volume industrial and construction use	Lowest price; limited pharmaceutical documentation
Cosmetic and food grade	Moderate regulatory and purity requirements	Higher price; broader supplier base
Pharmaceutical grade or pharmaceutical-qualified grade	Lower volume, high documentation burden	Highest relative price and switching costs

The pharmaceutical market is likely to track oral solid-dose manufacturing growth rather than pigment-industry growth. Generic tablets and capsules represent the largest recurring demand base. New drug launches add volume, but the majority of demand comes from established products with long commercial lives.

What is driving demand for CI 77499?

Generic and branded tablet production

Color-coded tablets reduce medication errors and help manufacturers distinguish strengths, markets, and products. Black or gray film coatings are used less frequently than white, yellow, red, or blue coatings, but CI 77499 remains relevant in selected product designs and combination colors.

Generic manufacturers also use pigments to reproduce reference-product appearance. Appearance matching can support regulatory submissions, brand recognition, and product-line differentiation.

Capsule and multiparticulate products

CI 77499 may be used in capsule shells, printing inks, pellets, and multiparticulate coatings. Demand rises when manufacturers use capsule color systems to distinguish dosage strengths or release profiles.

Film-coating systems

Pharmaceutical coating suppliers sell ready-to-use systems in which iron oxide is pre-dispersed with polymers, plasticizers, opacifiers, and other colorants. This shifts value from raw pigment toward formulation, technical service, and regulatory support.

Regulatory and quality requirements

Pharmaceutical manufacturers increasingly require documented control of elemental impurities under ICH Q3D. Iron is a permitted or necessary element in some formulations, but manufacturers still evaluate elemental profiles, impurity sources, and route-specific exposure. [4]

The commercial consequence is that a low-cost pigment supplier without pharmaceutical documentation may be unable to compete for regulated drug applications, even when its chemical composition is similar.

Who supplies pharmaceutical-grade black iron oxide?

The competitive landscape includes global synthetic iron oxide producers, specialty pigment manufacturers, pharmaceutical coating companies, and distributors. Relevant supplier categories include:

1. Synthetic iron oxide manufacturers with black grades.
2. Pharmaceutical excipient distributors.
3. Film-coating companies that incorporate CI 77499 into finished systems.
4. Cosmetic pigment companies with pharmaceutical qualification packages.
5. Regional suppliers serving generic-drug manufacturing hubs.

Major iron oxide producers and pigment companies include LANXESS, Cathay Industries, Venator, Toda Kogyo, and regional Chinese and Indian manufacturers. Product suitability must be assessed grade by grade. A company’s industrial iron oxide portfolio does not establish that every grade is acceptable for pharmaceutical use.

Colorcon and similar coating suppliers compete indirectly with raw-pigment manufacturers by selling complete coating systems. This can reduce the customer’s need to qualify CI 77499 as a standalone material, but it increases dependence on the coating supplier’s formulation and regulatory package.

How does CI 77499 pricing work?

CI 77499 pricing is shaped by purity, particle size, dispersion quality, packaging, order volume, qualification status, and geography. Public list prices are unreliable because pharmaceutical transactions are commonly negotiated through distributors or included in coating-system prices.

A practical pricing hierarchy is:

Product type	Relative price	Main buyer
Industrial black iron oxide	Low	Cement, plastics, coatings producers
Cosmetic-grade CI 77499	Medium	Cosmetics and personal-care manufacturers
Food or pharmaceutical-qualified pigment	Medium-high	Food, pharmaceutical, and nutraceutical producers
Pre-dispersed pharmaceutical coating	High on a formulation basis	Tablet and capsule manufacturers

Raw material costs include iron feedstock, oxidation or precipitation chemistry, filtration, drying, milling, classification, testing, packaging, and waste treatment. Energy prices affect synthetic pigment economics, especially where calcination or drying is energy-intensive.

Supplier margins are more defensible when the product has a drug-master-file package, established customer qualification, validated analytical methods, and a long change-control history. The pigment itself is chemically mature and difficult to differentiate. Documentation and supply assurance provide the primary commercial differentiation.

What is the financial trajectory for CI 77499?

The expected financial trajectory is low-single-digit volume growth with periodic price increases tied to energy, freight, labor, compliance, and raw-material costs. Revenue performance will vary sharply by supplier because CI 77499 is usually embedded in a wider iron oxide portfolio.

Base-case trajectory

The base case is stable demand from oral solid-dose pharmaceuticals, with modest growth in emerging-market generic production and contract manufacturing. Price realization should remain mixed:

• Industrial-grade pricing remains competitive.
• Pharmaceutical-qualified grades retain a premium.
• Pre-dispersed coating systems capture more value than raw pigment.
• Long-term contracts limit rapid price increases for established customers.
• Qualification barriers reduce short-term substitution.

Upside factors

Growth can exceed the broader pigment market if:

• Generic-drug production expands in India, China, Latin America, and Southeast Asia.
• Capsule and multiparticulate dosage forms gain share.
• Manufacturers dual-source pigments for supply security.
• Coating suppliers replace legacy pigments with compliant alternatives.
• Regulatory inspections increase demand for traceable, qualified excipients.

Downside factors

Revenue can weaken if:

• Customers reformulate toward uncolored or white dosage forms.
• Environmental controls raise manufacturing costs.
• Customers consolidate purchases through large coating-system suppliers.
• A major producer experiences contamination, recall, or supply interruption.
• Pharmaceutical manufacturers reduce inventory after supply-chain normalization.

Public financial statements from pigment manufacturers do not normally identify pharmaceutical CI 77499 sales. As a result, company-level exposure should be estimated from pharmaceutical-grade product lines, coating-system sales, geographic presence, and customer concentration rather than reported product revenue.

What patents protect CI 77499 and its pharmaceutical formulations?

CI 77499 is an old inorganic pigment with no meaningful composition-of-matter patent protection. The core material is commercially mature and available from multiple producers.

Patent protection may still arise in four areas:

Potential protection area	Commercial relevance
Pigment synthesis or precipitation process	Can protect particle size, morphology, purity, or yield
Surface treatment	May improve dispersion, compatibility, or stability
Pharmaceutical coating composition	May protect polymer-pigment combinations or processing conditions
Dosage-form design	May cover color-coded strengths, capsule systems, or release systems

Such patents generally protect a manufacturing process or formulation, not CI 77499 itself. Patent expiry dates must be assessed at the individual family level. There is no standard Orange Book exclusivity period for CI 77499 as a standalone material, and no Paragraph IV challenge is directed to the pigment itself.

What is the FDA regulatory status of CI 77499?

FDA status depends on the intended use and product formulation. Iron oxide provisions in Title 21 of the Code of Federal Regulations address permitted color use, while the FDA Inactive Ingredient Database provides product-specific evidence of excipient use. [1][2]

Key regulatory considerations include:

• Route of administration
• Concentration in the finished drug
• Particle-size specification
• Heavy-metal and elemental-impurity limits
• Identity and assay testing
• Microbiological quality
• Supplier change control
• Drug-master-file or equivalent documentation
• Compatibility with the coating polymer and solvent system

An FDA-listed inactive ingredient does not automatically authorize every CI 77499 grade for every drug product. The applicant remains responsible for demonstrating suitability in the specific dosage form.

What is the European regulatory status of CI 77499?

In Europe, black iron oxide is generally associated with iron oxides and hydroxides under E172 and with cosmetic CI 77499 nomenclature. Pharmaceutical use depends on the applicable European Pharmacopoeia requirements, national implementation, product route, and finished-product authorization.

European customers typically expect:

• Compliance with applicable Ph. Eur. monographs or internal specifications
• Control of elemental impurities under ICH Q3D
• Supplier quality agreements
• GMP-relevant documentation
• Formal notification of manufacturing or specification changes
• Traceability of raw materials and production sites

The regulatory value of a supplier’s documentation package can exceed the value of small differences in pigment price.

Are there biosimilar, generic-entry, or litigation risks?

CI 77499 has no biosimilar risk because it is not a biologic. Generic-entry risk is indirect. When a branded drug loses exclusivity, generic manufacturers may reproduce the dosage form, coating color, or capsule appearance. That can increase pigment demand, but it can also pressure excipient pricing.

There is no widely reported, CI 77499-specific patent litigation comparable to disputes involving active pharmaceutical ingredients, delivery technologies, or branded formulations. Litigation risk is more likely to arise from:

• Product contamination or specification failure
• Mislabeling of grade or regulatory status
• Supply interruption
• Pharmaceutical coating patent claims
• Contractual quality disputes
• Environmental or workplace claims involving pigment production

No material public settlement pattern is associated specifically with CI 77499 pharmaceutical use.

Which geographic markets are most important?

Asia is central to the demand outlook because it combines large generic-drug production, extensive contract manufacturing, and significant pigment manufacturing capacity. India is particularly important for generic tablets, capsules, and excipient procurement. China is important both as a pigment manufacturing base and as a large pharmaceutical market.

North America and Europe remain higher-value markets because qualification, documentation, and quality-system requirements support premium pricing. Latin America and Southeast Asia offer growth potential through expanding generic production and local pharmaceutical manufacturing.

Supplier qualification is often regional. A manufacturer approved for one site, market, or dosage form may still require separate qualification for another site or regulatory filing.

Key Takeaways

• CI 77499 is black iron oxide, primarily Fe3O4, used as a pharmaceutical colorant rather than a functional excipient.
• No reliable public source discloses a standalone global pharmaceutical CI 77499 market size.
• Demand follows tablet, capsule, generic-drug, and film-coating production.
• Pharmaceutical-qualified grades command a premium because of documentation, testing, and qualification requirements.
• The product has no meaningful composition-of-matter patent barrier.
• Formulation, surface-treatment, and manufacturing-process patents can create narrower protection.
• FDA and European status depends on route, concentration, grade, and finished-product authorization.
• There is no direct biosimilar risk and no material CI 77499-specific Paragraph IV or Orange Book litigation.
• Financial growth is likely to be modest, with stronger margins in qualified grades and pre-dispersed coating systems.
• The main commercial risks are supplier qualification failure, contamination, regulatory noncompliance, energy-cost inflation, and customer consolidation.

FAQs

Is CI 77499 the same as black iron oxide?

Yes. CI 77499 is the cosmetic color index designation generally used for black iron oxide, whose principal chemical phase is magnetite, Fe3O4.

Can CI 77499 be used in oral pharmaceutical tablets?

It can be used in some oral pharmaceutical products, but acceptance depends on the jurisdiction, dosage form, concentration, supplier grade, and applicable regulatory requirements.

Does CI 77499 have an Orange Book listing?

No. The Orange Book lists approved drug products and related patent and exclusivity information, not standalone excipients such as CI 77499.

Is CI 77499 more valuable as a raw pigment or as a coating system?

It generally captures more commercial value when incorporated into a qualified pharmaceutical coating system because the supplier provides formulation, dispersion, technical support, and regulatory documentation.

What is the main threat to CI 77499 suppliers?

The main threats are price competition from qualified regional manufacturers, customer consolidation with coating-system suppliers, raw-material and energy-cost inflation, and loss of qualification after a quality or supply failure.

References

1. U.S. Food and Drug Administration. (n.d.). 21 C.F.R. § 73.1200: Iron oxides. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/section-73.1200

2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. European Commission. (n.d.). EU food additive database: E172 iron oxides and hydroxides. https://food.ec.europa.eu

4. International Council for Harmonisation. (2014). ICH Q3D(R2): Guideline for elemental impurities. https://www.ich.org/page/quality-guidelines